CA-WETA-DIGITAL
17.12.2020 18:17:18 CET | Business Wire | Press release
Weta Digital, one of the world’s premiere visual effects facilities and parent company of Weta Animated, has announced the addition of industry leaders Tom Staggs, Jeff Huber and Ken Kamins to its Board of Directors. The appointment of Staggs, Huber and Kamins reflect the continued growth and innovation of the company, which is also opening offices in Los Angeles and San Francisco.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005350/en/
“Tom, Jeff and Ken are extraordinary additions to the board of Weta Digital,” said Prem Akkaraju, Global CEO of Weta Digital. “They have established best practices at the highest levels of company management, in entertainment and digital technology. Their combined business acumen and collective depth of experience perfectly positions Weta Digital for exponential growth. Opening offices in Los Angeles and San Francisco enables storytellers to tap Weta’s production pipeline and work with concept designers, animation supervisors and other key creatives, in both the US and New Zealand. Weta Digital’s expansion comes at a time when much of the film industry is experiencing extraordinary uncertainty as we grapple with the ongoing impact of Covid-19. We’re extremely fortunate that New Zealand got in front of the curve early - it’s one of the few places in the world that has managed community transmission, where you can make a film safely, without the restrictive protocols of other markets.”
Tom Staggs brings more than 26-years of experience at The Walt Disney Company, including 18 years of C-suite experience with the company. He was most recently Disney’s Chief Operating Officer, having previously served for five years as Chairman of Disney Parks and Resorts Worldwide and for nearly 12 years as Disney’s Chief Financial Officer. During his time at Disney, Staggs helped shape Disney’s strategic, financial, operational, creative and brand management strategies across every segment of the company and helped drive many of Disney’s most important initiatives including the acquisitions of Cap Cities/ABC, Pixar and Marvel. Since departing Disney in late 2016, Staggs has focused on developing several new business ventures across a variety of fields. He is a board member and advisor to a number of private companies, and also serves on the board of directors of music streaming service Spotify. Before joining Disney, Staggs was an investment banker at Morgan Stanley and Dain Bosworth.
“I have long admired Peter Jackson and Fran Walsh’s filmmaking talents and Weta Digital’s accomplishments in animation and visual effects. Weta Digital’s rare combination of creative talent and technology gives them a unique ability to succeed in high-end animation production,” said Staggs. “I look forward to working with Peter, Fran, Prem and the entire Weta Digital team on the animation business and further global expansion.”
Jeff Huber is the former Founding CEO and Vice Chairman of GRAIL and previously a Senior Vice President at Google. Having spent over 13 years at Google, Huber co-founded the company’s life sciences efforts in Google X and led development and scaling for Google Maps, Google Apps and Google Ads. During his tenure as an executive at Google, Jeff oversaw 50x growth in revenues (from $1 billion to >$50 billion) and organization (1,000 to >50,000 employees), and managed a $5 billion P&L and large distributed teams (5,000+ direct-line employees). Prior to Google, Huber served as Vice President of Architecture and Systems Development at eBay and Senior Vice President of Engineering at Excite@Home, where he led consumer product and infrastructure development.
"Weta Digital is known around the world for its astounding visual effects and inventive storytelling. This amazing artistry is driven by groundbreaking technology and non-stop innovation,” said Huber. “The research and development teams at Weta Digital have consistently produced magic and raised the bar as to what is possible. I look forward to the adventures ahead with Peter, Fran, Prem and the entire Weta Digital Team, growing the company in scale and technology excellence to create the next generation of culture-defining stories and experiences."
Ken Kamins is the Founder and CEO of Key Creatives, a management-production company. He has represented Peter Jackson and Fran Walsh since 1992, and his Executive Producer credits include The Hobbit Trilogy , District 9 , and The Adventures of Tintin: The Secret of the Unicorn. Prior to his current position, he served as Executive Vice President of the talent agency, International Creative Management; and before that, as Executive Vice President of RCA/Columbia Pictures Home Entertainment.
“I’ve had a front row seat for the entire growth curve of Weta Digital, from its beginnings in 1993 when the company consisted of just one computer and one artist creating the digital effects in “Heavenly Creatures”, through to this moment,” said Kamins. “Weta Digital was designed by Peter and Fran to be a creative haven for filmmakers - a place where they could let their imaginations run wild. No idea was too crazy or too difficult to try. In collaboration with the many great artists Weta has had the privilege to work with, Joe Letteri, David Conley and their teams have consistently pushed the boundaries of imaginative storytelling.”
Staggs, Huber and Kamins join Weta Digital board members Peter Jackson, Fran Walsh, Sean Parker, Joe Letteri and CEO Prem Akkaraju.
ABOUT WETA DIGITAL:
Weta Digital is the standard-bearer for creativity and innovation in visual effects and animation, attracting talent, partners, and clients that seek to push what is possible in pursuit of their artistic vision. Weta’s proprietary pipeline continues to evolve and provide artists with the tools they need to create their best work. Based in Wellington, New Zealand, Weta Digital is the largest single-site VFX studio in the world drawing artists from over 40 countries. They are some of the most creative and ambitious artists, engineers, and executives in entertainment and their work has earned six visual effects Academy Awards, ten Academy Sci-Tech Awards and six visual effects BAFTA Awards in addition to the 34 Visual Effects Society Awards awarded to them by their peers. Ground-breaking, performance-driven animated characters from Gollum to Caesar, and worlds from Middle-earth to Pandora, are regarded as some of the best visual effects ever to appear on screen.
For more information:
Corporate: www.wetastudios.com
Weta Digital: www.wetafx.co.nz
Follow: @weta_digital
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005350/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
